Indolent Non-Hodgkin Lymphoma — Trials

Indolent Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 212
Recruiting: 104
Ph III recruiting: 4
Growth YoY: +51.7%
Industry share: 20%
Top sponsor: City of Hope Medical Center
Termination share: 36.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (150)

clinicaltrialsPublishedShowing 151–177 of 177 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00003210	Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease	completed	Phase 2	105	National Cancer Institute (NCI)NIH	1	Apr 15, 2015	clinicaltrials
NCT00832234	Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia(BDR-WM)	completed	Phase 2	59	European Myeloma Network B.V.NETWORK	1	Feb 18, 2015